diosgenin has been researched along with verapamil in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ding, CH; Li, SL; Long, MH; Mao, Q; Shakya, S; Zhu, H; Zhu, SC | 1 |
Lee, EK; Lee, MJ; Moon, SY; Park, SK; Yang, WS | 1 |
2 other study(ies) available for diosgenin and verapamil
Article | Year |
---|---|
Study on the pharmacokinetics profiles of polyphyllin I and its bioavailability enhancement through co-administration with P-glycoprotein inhibitors by LC-MS/MS method.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B; Biological Availability; Caco-2 Cells; Cell Line, Tumor; Chromatography, Liquid; Cyclosporine; Diosgenin; Humans; Male; Rats; Rats, Sprague-Dawley; Saponins; Tandem Mass Spectrometry; Verapamil | 2015 |
Diosgenin, an Activator of 1,25D3-MARRS Receptor/ERp57, Attenuates the Effects of TNF-α by Causing ADAM10-Dependent Ectodomain Shedding of TNF Receptor 1.
Topics: ADAM10 Protein; Biological Transport; Calcium; Calcium Channels, L-Type; Cell Membrane; Cells, Cultured; Diosgenin; Egtazic Acid; Endothelial Cells; Humans; Intercellular Adhesion Molecule-1; Microscopy, Confocal; Protein Disulfide-Isomerases; Receptors, Tumor Necrosis Factor, Type I; RNA Interference; RNA, Small Interfering; Tumor Necrosis Factor-alpha; Verapamil | 2017 |